Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Acer Therapeutics Inc. (NASDAQ: ACER).

Full DD Report for ACER

You must become a subscriber to view this report.


Recent News from (NASDAQ: ACER)

Acer files U.S. marketing application for Edsivo for connective tissue disorder
Acer Therapeutics (NASDAQ: ACER ) has filed a New Drug Application (NDA) with the FDA seeking approval for EDSIVO (celiprolol) for the treatment of vascular Ehlers-Danlos syndrome (vEDS), a connective tissue disorder caused by defects in a gene that encodes collagen. The company has requ...
Source: SeekingAlpha
Date: October, 29 2018 09:15
Acer Therapeutics Submits NDA for EDSIVO(TM) for the Treatment of vEDS
Requests Priority Review NEWTON, Mass., Oct. 29, 2018 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and ultra-rare diseases with critical unmet medical need...
Source: GlobeNewswire
Date: October, 29 2018 08:30
Acer Therapeutics' Focus On Rare And Ultra-Rare Diseases: A Potentially Lucrative Business Model
ACER data by YCharts Acer Therapeutics Inc. (NASDAQ: ACER ) ("Acer" or the "Company") is a pharmaceutical company headquartered in Newton, Massachusetts. The Company went public on September 19, 2017 following a merger and plan of arrangement between Opexa Therapeutics and privately h...
Source: SeekingAlpha
Date: September, 25 2018 06:08
Daily Insider Ratings Round Up 8/22/18
InsiderInsights' Daily Round Up articles rate the "significance" of the top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the significance of an insider transaction, however, and there are many more "Signi...
Source: SeekingAlpha
Date: August, 24 2018 09:39
Acer Therapeutics to Present at the 20th Annual H.C. Wainwright Conference
NEWTON, Mass., Aug. 20, 2018 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and ultra-rare diseases with critical unmet medical need, today announced that Acer&#x...
Source: GlobeNewswire
Date: August, 20 2018 08:30
HTG Molecular Appoints Michelle R. Griffin to its Board of Directors
TUCSON, Ariz., Aug. 16, 2018 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM) (HTG), a provider of instruments, reagents, and services for molecular profiling applications, today announced the appointment of Ms. Michelle Griffin to its Board of Directors.  ȁ...
Source: GlobeNewswire
Date: August, 16 2018 16:01
Your Daily Pharma Scoop: Redhill Receives NoA, Regeneron Gets CRL, Stemline NDA Under Review
Stocks in News: RDHL, REGN RedHill Bio nabs U.S. patent covering RHB-104 and RHB-204 Discussion : RedHill Biopharma ( RDHL ) received a Notice of Allowance for its new formulation covering RHB-104 in Crohn's disease and RHB-204 in pulmonary nontuberculous mycobacteria infections. The ...
Source: SeekingAlpha
Date: August, 14 2018 08:58
Acer Therapeutics misses by $0.09
Acer Therapeutics (NASDAQ: ACER ): Q2 EPS of -$0.64 misses by $0.09 . More news on: Acer Therapeutics Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: August, 13 2018 16:19
Acer on track for Q4 NDA for Edviso for vEDS
Acer Therapeutics (NASDAQ: ACER ) Q2 results ($M): Operating expenses: 4.9 (+157.9%); net loss: (4.8) (-54.8%). More news on: Acer Therapeutics Inc., Healthcare stocks news, Earnings news and commentary, Read more ...
Source: SeekingAlpha
Date: August, 13 2018 16:09
Acer Therapeutics Reports Second Quarter 2018 Financial Results and Provides Corporate Update
Acer continues to progress towards goal of commercializing EDSIVO™ Company appoints VPs of Medical Affairs and Quality NEWTON, Mass., Aug. 13, 2018 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and...
Source: GlobeNewswire
Date: August, 13 2018 16:01

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-09-0831.0030.1631.52329.4441,389
2018-05-1719.2519.8219.8218.403314,123

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-146,72313,40650.1492Short
2018-12-134,3539,44946.0684Short
2018-12-121,8024,87037.0021Short
2018-12-111,3664,26232.0507Cover
2018-12-102091,93710.7899Cover

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on ACER.


About Acer Therapeutics Inc. (NASDAQ: ACER)

Logo for Acer Therapeutics Inc. (NASDAQ: ACER)

Not available

 

Contact Information

 

 

Current Management

  • Neil K. Warma / CEO

Current Share Structure

  • Market Cap: $137,802,819 - 05/14/2018
  • Issue and Outstanding: 7,497,433 - 03/01/2018

 


Recent Filings from (NASDAQ: ACER)

Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 15 2018
Amendment to a previously filed 8-A12B
Filing Type: 8-A12B/AFiling Source: edgar
Filing Date: May, 15 2018
Securities offered to employees under employee benefit plans
Filing Type: S-8Filing Source: edgar
Filing Date: May, 15 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 14 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 14 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 09 2018
Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities
Filing Type: 25-NSEFiling Source: edgar
Filing Date: April, 05 2018
Proxy soliciting materials. Revised preliminary material
Filing Type: PRER14AFiling Source: edgar
Filing Date: March, 30 2018
Proxy soliciting materials. Revised preliminary material
Filing Type: PRER14AFiling Source: edgar
Filing Date: March, 28 2018
Preliminary proxy statement providing notification matters to be brought to a vote
Filing Type: PRE 14AFiling Source: edgar
Filing Date: March, 12 2018

 

 


Daily Technical Chart for (NASDAQ: ACER)

Daily Technical Chart for (NASDAQ: ACER)


Stay tuned for daily updates and more on (NASDAQ: ACER)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: ACER)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in ACER is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of ACER and does not buy, sell, or trade any shares of ACER. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/